We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

NanoPass Collaborates with Pharma Partners in COVID-19 Vaccine Development

Product News   Apr 28, 2020

 
NanoPass Collaborates with Pharma Partners in COVID-19 Vaccine Development
FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

IRBM’s Advent Manufactures 13,000 Doses of COVID-19 Vaccine for Use in Phase 2/3 Clinical Trials

Product News

Advent has manufactured 13,000 doses of the novel COVID-19 vaccine candidate, ChAdOx1 nCoV-19 (now known as AZD1222) for use in the Phase 2/3 clinical trial COV002 by the University of Oxford.

READ MORE

Phase I/II Clinical Trial of COVID-19 Vaccine Begins

Product News

Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX‑CoV2373, a stable, prefusion protein made using its proprietary nanoparticle technology.

READ MORE

300 Antibodies Generated That Have Neutralization Potential Against SARS-CoV-2

Product News

Prellis Biologics, Inc. announced that it has generated 300 human IgG antibodies that bind to either the S1 or S2 spike protein of the SARS-CoV2-Wuhan strain of the novel coronavirus.

READ MORE

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE